Thomas James Doyle Sells 4,949 Shares of Kura Oncology, Inc. (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Kura Oncology Stock Performance

Kura Oncology stock traded down $0.12 during trading hours on Friday, hitting $7.91. 1,362,535 shares of the stock traded hands, compared to its average volume of 1,345,422. The firm's 50 day moving average price is $8.97 and its 200-day moving average price is $15.42. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $615.08 million, a price-to-earnings ratio of -3.35 and a beta of 0.81. Kura Oncology, Inc. has a 1 year low of $6.98 and a 1 year high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.01. During the same period in the previous year, the business posted ($0.50) earnings per share. As a group, equities analysts expect that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new stake in Kura Oncology in the third quarter valued at $25,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock worth $144,000 after buying an additional 1,750 shares during the last quarter. Rhumbline Advisers grew its holdings in Kura Oncology by 2.0% during the fourth quarter. Rhumbline Advisers now owns 99,991 shares of the company's stock worth $871,000 after acquiring an additional 1,923 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company's stock worth $793,000 after acquiring an additional 1,976 shares during the period. Finally, Harbor Capital Advisors Inc. raised its position in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after acquiring an additional 2,076 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on KURA shares. Wedbush restated an "outperform" rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. Lifesci Capital raised shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Cantor Fitzgerald reissued an "overweight" rating on shares of Kura Oncology in a research report on Monday, December 9th. Finally, Bank of America reduced their target price on Kura Oncology from $36.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, November 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $27.38.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.